Clean Science and Technology (NSE:CLEAN) filed the transcript of its Q1 FY27 earnings conference call with BSE and NSE on 6 August 2026, covering results for the quarter ended June 2026. The company reported its highest-ever consolidated quarterly sales of approximately Rs 264 crore, a 10% year-on-year rise, driven by the continued scale-up of its HALS business.
Key Highlights
- Standalone revenue rose 5% sequentially to Rs 203 crore, with EBITDA of Rs 87 crore and PAT of Rs 73 crore, representing margins of 43% and 36% respectively.
- Consolidated revenue grew 7% quarter-on-quarter to Rs 264 crore, with EBITDA of Rs 96 crore and PAT of Rs 73 crore at margins of 37% and 28% respectively.
- HALS now contributes 22% of consolidated sales, with exports accounting for nearly 50% of HALS revenue in Q1 FY27, up from an entirely domestic mix in the first year of sales.
- Clean Science entered a strategic collaboration with Swiss firm Geneus Chem for technology transfer and co-branded marketing of advanced NOR HALS grades, targeting Rs 300-350 crore in additional revenue over three to four years.
About the Company
Clean Science and Technology (NSE:CLEAN), headquartered in Pune, Maharashtra, is a specialty chemicals manufacturer listed on NSE. The company produces performance chemicals, pharma intermediates, and FMCG chemicals, including hydroquinone, catechol, and hindered amine light stabilisers (HALS). It operates manufacturing facilities in Kurkumbh, Pune, and conducts sales across domestic and international markets through its subsidiary Clean Fino-Chem Limited (CFCL).
Announcement in Detail
The transcript, filed under Regulation 30 of the SEBI Listing Regulations, covers the conference call held on 1 August 2026. Managing Director Siddharth Sikchi noted that geopolitical headwinds affected raw material supply chains and shipping vessel availability during the quarter, contributing to a 6% year-on-year moderation in standalone sales volumes. Despite these pressures, improved product-mix realisations lifted standalone sequential revenue by 5%.
On the HALS front, CFCL reached operational self-sufficiency during the quarter, shifting from an investment phase to monetisation. HALS volumes stood at approximately 1,000 tonnes in Q1 FY27, with average realisation moving from roughly Rs 440 per kg to Rs 550 per kg as product mix shifted toward higher grades. The Performance Chemical 2 plant is scheduled to be commercialised by Q3 FY27, and total capital infused into the subsidiary stands at approximately Rs 850 crore including Rs 100 crore during the quarter.
Impact on Investors
The filing shows that the share of the top four legacy products in consolidated sales has declined from 85% in Q4 FY23 to 60% in Q1 FY27, indicating a gradual diversification of the revenue base. Investors will note that the Geneus Chem collaboration involves geography-defined marketing rights and co-branding, meaning revenue from this arrangement is subject to commercialisation timelines and technology transfer completion, which management indicated targets Q3 FY27 for plant start-up.
Shareholders will observe that standalone PAT grew 37% sequentially after adjusting Q4 FY26 figures for one-off operating expenses. The disclosed terms indicate that HALS annualised revenue could reach Rs 250-300 crore based on Q1 volumes, as stated by management during the call, though this is a management projection and not an audited figure.
Sector / Market Context
India's specialty chemicals sector has been expanding its share of global supply chains, with government data and industry bodies such as FICCI noting sustained capacity additions by domestic manufacturers in performance and functional chemicals. The global HALS market is driven by demand from plastics, coatings, and agricultural film applications, where UV stabilisation requirements are increasingly stringent. Indian producers competing on cost and chemistry differentiation have been actively pursuing technology partnerships with European specialty chemical firms to access higher-margin product categories, a trend that the Geneus Chem collaboration reflects within this broader context.